Table 2.
IC regimens | N | Efficacya | ||||
---|---|---|---|---|---|---|
Average (%) | 0–25% | 25–50% | 50–100% | 100% | ||
TP | 13 | 47.8±20.5 | 2 | 5 | 6 | 0 |
PF | 34 | 55.8±22.1 | 1 | 13 | 20 | 0 |
TPF | 65 | 61.0±24.5 | 5 | 14 | 44 | 2 |
PF + Endostar | 3 | 87.1±7.9 | 0 | 0 | 3 | 0 |
TPF + Nimotuzumab | 6 | 70.8±20.9 | 0 | 0 | 6 | 0 |
Statistic analysis | F=2.515 | |||||
P=0.045* |
Reduction in the size of neck lymph node lesion followed by Fisher’s least significant difference (LSD) test.
P<0.05.